Director Toyin Ajayi granted 41,096 RSUs at Evolent Health (EVH)

Rhea-AI Filing Summary

Ajayi Toyin reported acquisition or exercise transactions in this Form 4 filing.

Evolent Health, Inc. reported that director Dr. Toyin Ajayi received an equity grant of 41,096 shares of Class A common stock in the form of restricted stock units under the company’s 2015 Omnibus Incentive Compensation Plan. After this award, Dr. Ajayi directly holds 75,170 shares. These restricted stock units vest on the earlier of June 4, 2027, or the date of Evolent Health’s 2027 annual meeting, assuming she continues to serve through the vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ajayi Toyin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	41,096	$0.00	--

Holdings After Transaction: Class A Common Stock — 75,170 shares (Direct)

Footnotes (1)

1. Represents restricted stock units granted to Dr. Ajayi pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

Key Figures

RSUs granted: 41,096 shares Grant price: $0.00 per share Total holdings after grant: 75,170 shares +1 more

4 metrics

RSUs granted 41,096 shares Restricted stock unit award to Dr. Toyin Ajayi

Grant price $0.00 per share Equity compensation grant with no cash purchase price

Total holdings after grant 75,170 shares Dr. Ajayi’s direct Class A common stock holdings post-transaction

Vesting date June 4, 2027 Earlier of June 4, 2027, or 2027 annual meeting

Key Terms

restricted stock units, Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, vest, Grant, award, or other acquisition

4 terms

restricted stock units financial

"Represents restricted stock units granted to Dr. Ajayi pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan financial

"Represents restricted stock units granted to Dr. Ajayi pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan."

vest financial

"Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/08/2026 - 04:29 PM Accepted by SEC EDGAR 06/08/2026 - 04:29 PM Learn about SEC filing dates

FAQ

What did Evolent Health (EVH) disclose about Dr. Toyin Ajayi’s recent equity grant?

Evolent Health disclosed that director Dr. Toyin Ajayi received 41,096 restricted stock units of Class A common stock. These units were granted under the company’s 2015 Omnibus Incentive Compensation Plan as part of her director compensation package.

How many Evolent Health (EVH) shares does Dr. Toyin Ajayi hold after this Form 4 transaction?

After the reported grant, Dr. Toyin Ajayi directly holds 75,170 shares of Evolent Health Class A common stock. This total includes the newly awarded 41,096 restricted stock units reflected in the Form 4 insider trading report.

When do Dr. Toyin Ajayi’s new Evolent Health (EVH) restricted stock units vest?

The restricted stock units granted to Dr. Ajayi vest on the earlier of June 4, 2027, or the date of Evolent Health’s 2027 annual meeting. Vesting is conditioned on her continued service with the company through that vesting date.

What type of transaction was reported in Evolent Health’s (EVH) latest Form 4 for Dr. Ajayi?

The Form 4 reports an “A” code transaction, meaning a grant, award, or other acquisition. Dr. Ajayi received 41,096 restricted stock units at no cash cost per share as part of her compensation for board service.

Under which plan were Dr. Toyin Ajayi’s Evolent Health (EVH) restricted stock units granted?

The restricted stock units were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. This plan governs equity-based awards such as RSUs issued to directors, executives, and other eligible participants.

Does the Evolent Health (EVH) Form 4 indicate any share sales by Dr. Ajayi?

The Form 4 indicates only an acquisition of shares through a restricted stock unit grant and no reported sales. The transaction code is “A,” reflecting a grant or award rather than any disposition of existing Evolent Health shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ajayi Toyin

(Last) (First) (Middle)

C/O EVOLENT HEALTH, INC.

1812 N. MOORE ST., STE. 1705

(Street)

ARLINGTON VIRGINIA 22209

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evolent Health, Inc. [ EVH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	06/04/2026		A		41,096(2)	A	$0	75,170	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units granted to Dr. Ajayi pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

2. Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

Remarks:

	/s/ Jonathan Weinberg, Attorney-in-fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)